Naltrexone (Vivitrol)

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Opioid and Alcohol Dependence

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (14)
Other / comorbidity
NCT03232346 · New York State Psychiatric Institute
2017-08-01 – 2021-06-30 · Opioid-use Disorder
What this study did
NCT03078075 · University of Texas Southwestern Medical Center
2017-05-05 – 2019-07-25 · Methamphetamine Use Disorder
What this study did
NCT01389167 · Yale University
2011-09 – 2017-05 · Opiate Dependence
What this study did
NCT01100853 · University of Pennsylvania
2010-05 – 2013-02 · Amphetamine Dependence
What this study did
NCT00834080 · Alkermes, Inc.
2009-03 – 2012-05 · Opiate Dependence
What this study did
NCT00501631 · Alkermes, Inc.
2007-07 – 2011-03 · Alcohol Dependence
What this study did
NCT00678418 · Alkermes, Inc.
2008-06 – 2010-11 · Opiate Dependence
What this study did
NCT00156936 · Alkermes, Inc.
2004-08 – 2007-01 · Alcoholism, Opiate Dependence
What this study did
NCT00156923 · Alkermes, Inc.
2003-10 – 2007-01 · Alcoholism
What this study did
NCT01218997 · Alkermes, Inc.
2003-08 – 2005-03 · Alcoholism
What this study did
NCT01218971 · Alkermes, Inc.
2002-08 – 2004-09 · Alcohol Dependence
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT03113409 · New York State Psychiatric Institute
2017-06-01 – 2020-12-01 · Opioid-use Disorder
What this study did
Phase 2 (7)
Other / comorbidity
NCT03852628 · Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
2019-05-20 – 2023-01-30 · Post Traumatic Stress Disorder, Alcohol Abuse
What this study did
NCT04139668 · Centre for Addiction and Mental Health
2021-06-09 – 2022-06-13 · Cannabis Use Disorder
What this study did
NCT01587196 · University of Pennsylvania
2012-01 – 2021-01-01 · Prescription Opiate/Medication Dependence
What this study did
NCT01556425 · Johns Hopkins University
2012-05 – 2017-08-06 · Opioid Dependence
What this study did
NCT01690546 · Paolo Mannelli
2012-09 – 2015-02 · Opiate Dependence
What this study did
NCT00777062 · University of Pennsylvania
2009-07 – 2013-09 · Cocaine Dependence, Alcohol Dependence
What this study did
NCT01218984 · Alkermes, Inc.
2002-03 – 2003-05 · Opiate Dependence
What this study did
Phase 1 (5)
Other / comorbidity
NCT07064564 · Akyso Therapeutics, LLC
2026-07-25 – 2029-12-31 · Opioid Use Disorder
What this study did
NCT07269873 · BioCorRx Pharmaceuticals Inc
2026-03-16 – 2026-12-05 · Healthy Adult Male and Female Volunteers
What this study did
NCT06374290 · The University of Texas Health Science Center, Houston
2024-07-16 – 2024-12-04 · Smoking Cessation
What this study did
NCT04716881 · Go Medical Industries Pty Ltd
2021-01-25 – 2022-04-04 · Opioid-use Disorder
What this study did
NCT01377610 · New York State Psychiatric Institute
2011-06 – 2017-12 · Opioid Dependence
What this study did
Phase 4 (7)
Other / comorbidity
NCT04094584 · University of California, San Francisco
2020-08-14 – 2022-05-01 · Alcohol Use Disorder, Substance Use, Alcohol Abuse or Dependence
What this study did
NCT02978417 · Duke University
2017-09-21 – 2019-06-30 · Opioid-Related Disorders
What this study did
NCT01563718 · Rhode Island Hospital
2012-03 – 2015-08 · Substance-Related Disorders
What this study did
NCT01453374 · Alkermes, Inc.
2011-01 – 2014-05 · Opioid Dependence
What this study did
NCT00620750 · NYU Langone Health
2007-07 – 2010-02 · Alcohol Dependence
What this study did
NCT00511836 · Alkermes, Inc.
2007-07 – 2009-10 · Alcohol Dependence
What this study did
NCT00537745 · Pacific Institute for Research and Evaluation
2007-04 – 2009-05 · Alcohol Consumption
What this study did
Early phase / not applicable (2)
Other / comorbidity
NCT01077310 · Yale University
2010-08 – 2015-08 · Alcohol Dependence, Problem Drinking, Hazardous Drinking, Human Immunodeficiency Virus, AIDS
What this study did
NCT00675532 · Yale University
2011-05 – 2013-08 · Drug Dependence
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (1)
Other / comorbidity
NCT04454411 · University of Pennsylvania
2022-08-01 – 2024-08-31 · Opioid Dependence
What this study did
Phase 1 (2)
Other / comorbidity
NCT05620940 · Inventage Lab., Inc.
2024-09-11 – 2025-12-30 · Opioid Dependence, Alcohol Dependence, Multiple Sclerosis
What this study did
NCT04828694 · BioCorRx Inc
2022-06-17 – 2023-03-22 · Opioid-use Disorder
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Other / comorbidity
NCT00476242 · New York State Psychiatric Institute
2008-06 – 2011-08 · Opioid Dependence, Heroin Dependence
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Opioid and Alcohol Dependence: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Naltrexone (Vivitrol): this drugApprovedSmall moleculeOpioid receptorPartial signalNo reviewed efficacy summary in this indication
Nalmefene Nasal Spray (OPVEE)
Approved(overall)
Small moleculeOpioid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
Naloxone (Narcan)
Approved(overall)
Small moleculeOpioid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication
NaltrexoneApprovedSmall moleculeOpioid receptors (mu-opioid receptor)not yet gradedNo reviewed efficacy summary in this indication
Naltrexone / Acetaminophen (ALLOD-2)
Phase 2/3(overall)
—Opioid receptor
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Naltrexone (Vivitrol) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Healthy Adult Male and Female VolunteersRecruiting
Est. primary completion 2026-12-05 · NCT07269873 · CT.gov ↗
What to watch
2029 (1)
October 2029 (1)
Phase 1Opioid Use DisorderActive not recruiting
Est. primary completion 2029-10-01 · NCT07064564 · CT.gov ↗
What to watch

See the full readout calendar ↗